Pharmacology of argatroban

Expert Review of Hematology

Volumn 3, Issue 5, 2010, Pages 527-539

  Jeske, Walter P ^a   Fareed, Jawed ^a   Hoppensteadt, Debra A ^a   Lewis, Bruce ^a   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulant; antithrombin; argatroban; cardiovascular disease; direct thrombin inhibitor; heparin induced thrombocytopenia; ischemic stroke; percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIPLASMIN; APIXABAN; ARGATROBAN; ARGININE; BLOOD CLOTTING FACTOR 10A; CD40 LIGAND; DABIGATRAN; DESULFATOHIRUDIN; DIGOXIN; EPTIFIBATIDE; ERYTHROMYCIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN; LIDOCAINE; PADGEM PROTEIN; PARACETAMOL; PLASMIN; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 1; RIVAROXABAN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRYPSIN; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BYPASS SURGERY; CEREBROVASCULAR ACCIDENT; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EXTRACORPOREAL CIRCULATION; GENDER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ISOMER; KIDNEY INJURY; LIVER INJURY; MULTIPLE ORGAN FAILURE; OBESITY; PRIORITY JOURNAL; PROTHROMBIN TIME; RESTENOSIS; REVIEW; STROKE; SYNDROME; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTITHROMBINS; EUROPEAN UNION; FEMALE; HEPARIN; HUMANS; ISOMERISM; JAPAN; MALE; PEPTIDOMIMETICS; PIPECOLIC ACIDS; STROKE; THROMBIN; THROMBOCYTOPENIA; THROMBOSIS; UNITED STATES;

EID: 78049417541     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.53     Document Type: Review

References (99)

1. Kobayashi W, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin. Thromb. Hemost. 23, 531-534 (1997). (Pubitemid 28114049)
2. Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III defciency. Nephrol. Dial. Transplant. 18, 1623-1630 (2003). (Pubitemid 36939638)
3. Miyata S, Yamamoto H, Kamei M et al. Heparin-induced thrombocytopenia clinical studies and the effcacy of argatroban in Japan. Semin. Thromb. Hemost. 34(Suppl. 1), 37-47 (2008).
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. Chest 133, S160-S198 (2008).
5. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs 69(13), 1829-1851 (2009).
6. Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin. Investig. Drugs 17(12), 1937-1945 (2008).
7. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28(11), 1354-1373 (2008).
8. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin. Pharmacokinet. 48(1), 1-22 (2009).
9. Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc. Drug Rev. 9(3), 247-263 (1991).
10. Kikumoto R, Tamao Y, Tezuka T et al. Selective inhibition of thrombin by (2R, 4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L- arginyl)]-2-piperidinecarboxylic acid. Biochemistry 23, 85-90 (1984). (Pubitemid 14181541)
11. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fbrin-or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb. Haemost. 72, 381-386 (1994). (Pubitemid 24280776)
12. Hara H, Yoshikuni T, Kikumoto R. Effect of argatroban (MD-805) on platelet function. Jap. J. Pharm. Ther. 14(Suppl. 1), 13-19 (1986). (Pubitemid 17186774)
13. Ueki Y, Matsumoto K, Kizaki Y et al. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo-controlled study. J. Thromb. Thrombolysis 8(2), 131-137 (1999). (Pubitemid 29410838)
14. Rawson TE, Van Gorp KA, Yang J, Kogan TP. Separation of 21-(R)-and 21-(S)-argatroban: solubility and activity of the individual diastereoisomers. J. Pharm. Sci. 82(6), 672-673 (1993). (Pubitemid 23216020)
15. Yeh R, Jang IK. Argatroban; update. Am. Heart J. 151, 1131-1138 (2006).
16. Ansara AJ, Arif S, Warhurst RD. Weight-based argatroban dosing nomogram for treatment of heparin-induced-thrombocytopenia. Ann. Pharmacother. 43(1), 9-18 (2009).
17. Ahsan A, Ahmad S, Iqbal O et al. Comparative studies on the biochemical and pharmacological properties of a major metabolite of argatroban (M1) [Abstract]. Thromb. Haemost. 178(Suppl. 1), 92 (1997).
18. Hursting MJ, Alford KL, Becker JC et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Hemost. 23, 503-516 (1997).
19. Hursting MJ, Murray PT. Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron 109(2), 80-94 (2008).
20. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20, 318-329 (2000).
21. Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J. Thromb. Thrombolysis 22(3), 169-176 (2006).
22. Husting MJ, Jang IK. Impact of renal function on argatroban therapy during percutaneous coronary intervention. J. Thromb. Thrombolysis 29, 1-7 (2010).
23. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 129(5), 1167-1175 (2006). (Pubitemid 44857777)
24. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J. Pediatr. Hematol. Oncol. 28(1), 4-10 (2006). (Pubitemid 43361611)
25. Hursting MJ, Jang IK. Effect of body mass index on argatroban therapy during percutaneous coronary intervention. J. Thromb. Thrombolysis 25(3), 273-279 (2008). (Pubitemid 351772730)
26. Begelman SM, Baghdasarian SB, Singh IM, Militello MA, Hursting MJ, Bartholomew JR. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J. Intensive Care Med. 23(5), 313-320 (2008).
27. Keegan SP, Gallagher EM, Ernst NE, Young EJ, Mueller EW. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confrmed heparin-induced thrombocytopenia. Ann. Pharmacother. 43, 19-27 (2009).
28. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. Chest 133, S340-S380 (2008).
29. Clark RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specifc thrombin inhibitor in man. Circulation 83, 1510-1518 (1991).
30. Tran JQ, DiCicco RA, Sheth SB. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J. Clin. Pharmacol. 39, 513-519 (1999).
31. Inglis AL, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco RA. Investigation of interaction between argatroban and acetaminophen, lidocaine, or digoxin. Am. J. Health Syst. Pharm. 59, 1258-1266 (2002).
32. Tamao Y, Yamamoto T, Hirata T, Kinusaga M, Kikumoto R. Effect of argatroban on blood coagulation. Jap. J. Pharm. Ther. 14(5), 7-12 (1986).
33. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb. Res. 105, 401-405 (2002). (Pubitemid 34621257)
34. Jeske W, Walenga JM, Lewis BE, Fareed J. Pharmacology of argatroban. Expert Opin. Investig. Drugs 8, 625-654 (1999). (Pubitemid 29213309)
35. Fareed J, Jeske WP. Small-molecule direct antithrombins: argatroban. Best Pract. Res. Clin. Haematol. 17(1), 127-138 (2004). (Pubitemid 38780071)
36. Fareed J, Hoppensteadt D, Iqbal O, Tobu M, Lewis BE. Practical issues in the development of argatroban: a perspective. Pathophys. Haemost. Thromb. 32(Suppl. 3), 56-65 (2002). (Pubitemid 37449305)
37. Weitz JI, Crowther MA. New anticoagulants; current status and future potential. Am. J. Cardiovasc. Drugs 3, 201-209 (2003). (Pubitemid 36840978)
38. Lewis BE, Walenga JM, Hursting MJ. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Cardiovasc. Rev. Rep. 23(8), 445-454 (2002).
39. LaMonte MP, Brown PM, Hursting MJ. Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Future Drugs 3(1), 31-41 (2005).
40. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101(1), 31-37 (2003).
41. Levine RL, Hursting MJ, Drexler A, Lewis BE, Francis JL. Heparin-induced thrombocytopenia in the emergency department. Ann. Emerg Med. 44(5), 511-515 (2004). (Pubitemid 39425053)
42. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia. A critical review. Arch. Intern. Med. 164, 361-369 (2004).
43. Hursting MJ, Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf. 32(3), 203-218 (2009).
44. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838-1843 (2001). (Pubitemid 32328395)
45. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG; Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern. Med. 163, 1849-1856 (2003). (Pubitemid 36960936)
46. Matthai WH, Hursting MJ, Lewis BE, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb. Res. 116(2), 121-126 (2005). (Pubitemid 40720188)
47. Greinacher A, Janssens U, Berg G et al.; for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100(6), 587-593 (1999). (Pubitemid 29379746)
48. Greinacher A, Volpel H, Janssens U et al.; for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99, 73-80 (1999). (Pubitemid 29035960)
49. Veach SA, Franks AM, Allan MC. Severe anaphylactic reaction after repeated intermittent exposure to lepirudin. Pharmacotherapy 27(5), 760-765 (2007).
50. Harenberg J, Jorg I, Fenyvesi T, Piazolo L. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J. Thromb. Thrombolysis 19(1), 65-69 (2005). (Pubitemid 40959217)
51. Kemkes-Matthes B, Walenga JM, Harenberg J, Fareed J. Argatroban treatment for patients with intolerance to heparin and hirudin. Clin. Appl. Thromb. Hemost. 11(1), 99-103 (2005). (Pubitemid 40194205)
52. Smythe MA, Stephens JL, Koerber JM, Mattson JC. A comparison of lepirudin and argatroban outcomes. Clin. Appl. Thromb. Hemost. 11(4), 371-374 (2005).
53. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 24 (6), 489-499 (2007). (Pubitemid 46974912)
54. Lewis BE, Matthai WH Jr, Cohen M et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin induced thrombocytopenia. Catheter Cardiovasc. Interv. 57, 177-184 (2002).
55. Cruz-Gonzalez I, Sanchez-Ledesma M, Osakabe M et al. What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention? Blood Coagul. Fibrinolysis 19(5), 401-404 (2008).
56. Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, non-randomized trial. J. Thromb. Thrombolysis 18(1), 31-37 (2004). (Pubitemid 40361646)
57. Cox DS, Kleiman NS, Boyle DA et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention. J. Clin. Pharm. 44(9), 981-990 (2004).
58. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ et al. Effcacy and safety or argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J. Thromb. Thrombolysis 25(2), 214-218 (2008). (Pubitemid 351583670)
59. Hirahara T, Kubo N, Ohmura N et al. Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction. J. Cardiol. 44(2), 47-52 (2004). (Pubitemid 40756153)
60. Itoh T, Nonogi H, Miyazaki S et al. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: a prospective randomized pilot study. Circ. J. 68(7), 615-622 (2004). (Pubitemid 38899593)
61. Roessig L, Genth-Zotz S, Rau M et al. Argatroban for elective percutaneous coronary intervention: the ARG-EO4 multi-center study. Int. J. Cardiol. DOI: 10.1016/j.ijcard.2010.02.044. (2010) (Epub ahead of print).
62. Cetta F, Graham LC, Wrona LL, Arruda MJ, Walenga JM. Argatroban use during pediatric interventional cardiac catheterization. Cath. Cardiovasc. Interv. 61(1), 147-149 (2004). (Pubitemid 38036807)
63. Vermeer F, Vahanian A, Fels PW et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J. Thromb. Thrombolysis 10, 233-240 (2000). (Pubitemid 32042086)
64. Nagatsuna T, Nomura S, Suehiro E, Fujisawa H, Koizumi H, Suzuki M. Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage; histopathological assessment. Cerebrovasc. Dis. 19(3), 192-200 (2005). (Pubitemid 40754338)
65. LaMonte MP, Nash ML, Wang DZ et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 35(7), 1677-1682 (2004).
66. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med. 32(4), 976-980 (2004). (Pubitemid 38471518)
67. Murray PT, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban regimens during hemodialysis in end-stage renal disease. Kidney Int. 66(6), 2446-2453 (2004).
68. Tang IY, Cox DS, Patel K et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann. Pharmacother. 39(2), 231-236 (2005). (Pubitemid 40165210)
69. Young G, Yonekawa KE, Nakagawa P, Nugent DJ. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion 19(5), 283-288 (2004). (Pubitemid 39359404)
70. Johnston N, Wait M, Huber L. Argatroban in adult extracorporeal membrane oxygenation. J. Extra Corpor. Technol. 34, 281-284 (2002). (Pubitemid 36569293)
71. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol. Oncol. Clin. N. Am. 14, 4445-4457 (2000). (Pubitemid 30241190)
72. Mejak B, Giacomuzzi C, Heller E et al. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J. Extra Corpor. Technol. 36(2), 178-181 (2004). (Pubitemid 38924747)
73. Kawada T, Mieda T, Abe H et al. Left heart bypass with the bio-medicus centrifugal pump by the use of an antithrombin agent, argatroban. Kyobu Geka 47, 803-808 (1994).
74. Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann. Thorac. Surg. 75, 1622-1624 (2003).
75. Kamei M, Miyata S, Niwaya K et al. Successful argatroban anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II. J. Thromb. Hemost. 1(Suppl. 1), P1162 (2003).
76. Tokuda Y, Matsumoto M, Sugita T et al. Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia. Circ. J. 67, 899-890 (2003). (Pubitemid 37229231)
77. Malherbe S, Tsui BCH, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 100, 443-445 (2004). (Pubitemid 38133716)
78. Dyke PC, Russo P, Mureebe L, Russo J, Tobias JD. Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Paediatr. Anaesth. 15, 328-333 (2005). (Pubitemid 40462810)
79. Mejak B, Giacomuzzi C, Shen I, Boshkov L, Ungerleider R. Cardiopulmonary bypass using argatroban as an anticoagulant for a 6.0-kg pediatric patient. J. Extra. Corpor. Technol. 37, 303-305 (2005). (Pubitemid 43160412)
80. Alsouf B, Boshkov LK, Kirby A et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Ann. 7, 155-171 (2004). (Pubitemid 38678734)
81. Kieta DR, McCammon AT, Holman WL, Nielsen VG. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth. Analg. 96, 956-958 (2003). (Pubitemid 36359022)
82. Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary artery bypass. Heart Vessels 18, 40-42 (2003). (Pubitemid 36442905)
83. Arnoletti JP, Whitman GJR. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann. Thorac. Surg. 68, 576-578 (1999). (Pubitemid 29521120)
84. Ide H, Fujiki T, Sato M, Endo H, Imamura K, Sudo K. Off-pump coronary artery bypass for a heparin-allergic patient. Jpn. J. Thorac. Cardiovasc. Surg. 49, 250-254 (2001).
85. Cannon MA, Butterworth J, Riley RD, Hyland JM. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann. Thorac. Surg. 77, 711-713 (2004). (Pubitemid 38186543)
86. Lubenow N, Selleng S, Wollert HG, Eichler P, Mullejans B, Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann. Thorac. Surg. 75(2), 577-579 (2003). (Pubitemid 36184517)
87. Hoffman WD, Czyz Y, McCollum DA, Hursting MJ. Reduced argatroban doses after coronary artery bypass graft surgery. Ann. Pharmacother. 42(3), 309-316 (2008). (Pubitemid 351429594)
88. Hursting MJ, Verme-Gibboney CN. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J. Cardiovasc. Pharm. 52(6), 561-566 (2008).
89. Gray E, Harenberg J; on behalf of the ISTH Control of Anticoagulation SSC Working Group on Thrombin Inhibitors. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. J. Thromb. Haemost. 3, 2096-2097 (2005). (Pubitemid 43086069)
90. Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul. Fibrinolysis 16, 251-257 (2005). (Pubitemid 40705046)
91. Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J. Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin. Appl. Thromb. Hemost. 8(3), 217-224 (2002).
92. Gosselin RC, Dager WE, King JH et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol. 121, 593-599 (2004).
93. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemost. 85, 435-440 (2001). (Pubitemid 32233014)
94. Harder S, Graff J, Klinkhardt U et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on PT, aPTT and ecarin clotting time. Thromb. Haemost. 91, 1137-1145 (2004).
95. Walenga JM, Drenth AF, Mayuga M et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clin. Appl. Thromb. Hemost. 14(3), 325-331 (2008). (Pubitemid 351871948)
96. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin. Appl. Thromb. Hemost. 11(3), 279-287 (2005). (Pubitemid 41022857)
97. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. Chest 133, S141-S159 (2008).
98. Gosselin RC, Dager WE, King JH et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol. 121, 593-599 (2004).
99. Gorman R, Gordan L, Zumberg M, Kitchens C. Successful use of argatroban as an anticoagulant in burn-related severe acquired antithrombin III defciency after heparin failure. Thromb. Haemost. 86, 1596-1597 (2001). (Pubitemid 34007547)